REGN - Regeneron Pharmaceuticals Inc. (REGN) Management Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
2024-03-12 13:35:31 ET
Regeneron Pharmaceuticals, Inc. (REGN)
Barclays 26th Annual Global Healthcare Conference Transcript
March 12, 2024, 11:15 AM ET
Executives
Chris Fenimore - Chief Financial Officer
Ryan Crowe - Vice President, Investor Relations
Analysts
Carter Gould - Barclays
Presentation
Carter Gould
Great. All right. Good morning. And welcome to the Barclays Global Healthcare Conference. My name is Carter Gould covering large-cap biopharma here at Barclays. Welcome, everyone. I’m pleased to welcome Regeneron Pharmaceuticals to the stage. Joining us, Chris Fenimore, newly-minted CFO and who Heads the IR. Ryan’s going to make some opening comments and then we’ll launch into Q&A.
Ryan Crowe
Yeah. Some quick forward-looking statements here. I’d like to remind you that our remarks made today may include forward-looking statements about Regeneron. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. The description of material risks and uncertainties can be found in Regeneron’s SEC filings. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Carter?
Question-and-Answer Session
Q - Carter Gould
All right. Pretty sure you can do that in your sleep now, Ryan. Chris, so I think we were just talking about a month into the new role. Your predecessor was there for a decade plus in that role. As we think now about you taking on this role, do you think about any sort of shifts in priorities or shifts in how you view capital allocation?...
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)